Date: September 16, 2025
Time: 11:00 am to 12:30 pm
Room: Grand Ballrooms 7 - 8 (Third Floor Level)
Track: Traditional Special Interest Group (SIG)
This session will review updates in autoimmune neurologic disorders of the central nervous system and in multiple sclerosis. It will focus on fluid‑based biomarkers (e.g., serum neurofilament light chain and glial fibrillary acidic protein) in MS and autoimmune neurologic disorders, including their prognostic value and how they should be incorporated into clinical practice. Moreover, their use in upcoming or published diagnostic criteria will be covered. We will also review new antibody discoveries and the utility of novel identification techniques—such as phage display—highlighting recently discovered neural antibodies exemplifying these methodologies. Additionally, we will explore how antibody testing can be expanded globally with innovative approaches to reach those who currently lack access, offering testing that is more affordable and less resource‑intensive for these regions. Finally, the session will cover the latest understanding of immune‑mediated neurologic disorders of the central nervous system.
At the conclusion of the session, attendees should be able to:
This presentation will be an overview of evidence support the utility of NFL and other fluid-based biomarkers in MS and antibody-associated demyelinating disease (NMOSD and MOGAD).
This presentation will explore cutting-edge techniques in antibody discovery, representing significant advancements and offering new insights and opportunities.
This presentation will give a report of global data on testing for AQP4 and MOG among people with clinically diagnosed NMOSD, alongside case examples of barriers to NMOSD care.
This presentation will provide a retrospective study on the presence of movement disorders and associated characteristics, etiologies, and outcomes in all causes of encephalitis.
In this presentation, we will discuss comprehensive serum proteomics identified proteins in MS associated with disability, MRI, OCT, and PROs, aiding biomarker and pathway discovery.